An observational study in Thrombosis, Pulmonary Embolism and Enoxaparin, sponsored by Medical University of Vienna. Recruiting at 3 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Medical University of Vienna · Observational
The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and/or pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are:
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
This study's planned enrollment of 1,300 is above the median of 173 across 384 observational studies indexed under Thrombosis.
Browse Thrombosis studies →Medical University of Vienna is the lead sponsor of 1,109 studies on the registry; 184 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients admitted to an surgical or medical intensive care unit who do not receive therapeutic anticoagulation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who are admitted to an participating intensive care unit who do not receive therapeutic anticoagulation.
Diagnostic Test: Anti-factor Xa activity calibrated for enoxaparin
Anti-factor Xa activity calibrated for enoxaparin
Number of patients with new-onset venous thromboembolism
New-onset deep vein thrombosis and/or new-onset pulmonary embolism. Both symptomatic and incidental events are included.
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of patients with new-onset upper extremity deep vein thrombosis
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of patients with new-onset lower extremity deep vein thrombosis
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of patients with new-onset central vein thrombosis
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of patients with new-onset symptomatic upper extremity deep vein thrombosis
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of patients with new-onset symptomatic lower extremity deep vein thrombosis
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of patients with new-onset incidental upper extremity deep vein thrombosis
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of patients with new-onset incidental lower extremity deep vein thrombosis
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of patients with new-onset pulmonary embolism
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of patients with new-onset symptomatic pulmonary embolism
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of patients with new-onset incidental pulmonary embolism
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of patients with venous thromboembolism
Time frame: prevalent at study enrolment
Number of patients with deep vein thrombosis
Time frame: prevalent at study enrolment
Number of patients with pulmonary embolism
Time frame: prevalent at study enrolment
Number of patients with new-onset venous thromboembolism
Time frame: 90 days after study enrolment
Number of days with any bleeding
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of days with major and/or fatal bleeding
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of red blood cell concentrates administered
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Number of days on which either procoagulant medication, platelet transfusion or fresh frozen plasma was administered
Time frame: until discharge from the intensive care unit or up to 14 days after study inclusion
Length of stay in the intensive care unit
Time frame: 90 days after study enrolment
Length of stay in the hospital
Time frame: 90 days after study enrolment
Death
Time frame: 90 days after study enrolment
Days alive and out of the intensive care unit
Time frame: 90 days after study enrolment
Days alive and out of the hospital
Time frame: 90 days after study enrolment
European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) index value
Minimum -1.0, Maximum 1.0; An index value of 1.0 indicates the best possible state of health. Index values below 0.0 indicate the worst possible state of health.
Time frame: 90 days after study enrolment
European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) visual analogue scale
Minimum 0. Maximum 100. A value of 0 indicates the worst possible state of health while a value of 100 indicates the best possible state of health.
Time frame: 90 days after study enrolment
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for May 2027, 36 months after the start.
Of 160 non-industry observational studies under Thrombosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 114. This study's planned 36 months is close to that.
Counting every sponsor, half of 189 studies reached it within 31 months; a quarter within 12 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →